Our findings provide insights into apoptotic resistance mechanisms and investigate the combination of direct BAX activation and BCL-XL inhibition as a novel therapeutic strategy that can broadly overcome apoptotic resistance in cancer. The gene discussed is BAX; the disease is cancer.